Braf V600E mutation in melanoma: translational current scenario

被引：0
作者：
J. A. Guadarrama-Orozco
A. Ortega-Gómez
E. B. Ruiz-García
H. Astudillo-de la Vega
A. Meneses-García
C. Lopez-Camarillo
机构：
[1] National Cancer Institute,Translational Medicine Laboratory
[2] Medical Center Siglo XXI,Laboratory of Translational Cancer Research and Cellular Therapy, Oncology Hospital
[3] National Cancer Institute,Genomics Sciences Program
[4] Autonomous University of Mexico City,undefined
来源：
Clinical and Translational Oncology | 2016年 / 18卷
关键词：
Melanoma; BRAF; V600E; Inhibitor resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Melanoma was one of the translational cancer examples in clinic, including target therapy related to specific biomarkers impacting in the outcome of melanoma patients. Melanomagenesis involved a wide variety of mutations during his evolution; many of these mutated proteins have a kinase activity. One of the most cited proteins in melanoma is BRAF (about 50–60 % of melanomas harbors activating BRAF mutations), for these the most common is a substitution of valine to glutamic acid at codon 600 (p.V600E). Therefore, the precise identification of this underlying somatic mutation is essential; knowing the translational implications has opened a wide view of melanoma biology and therapy.
引用
收藏
页码：863 / 871
页数：8
相关论文
共 61 条
[1]  
Merrill RM(2010)Cutaneous malignant melanoma among white hispanics and non-hispanics in the United States Ethn Dis 20 353-358
[2]  
Pace ND(2004)The RAF proteins take centre stage Nat Rev Mol Cell Biol 5 875-885
[3]  
Elison AN(2004)Oncogenic mutations in B-Raf Cell 116 764-766
[4]  
Wellbrock C(2004)The RAF proteins take centre stage Nat Rev Mol Cell Biol 5 875-885
[5]  
Karasaridis M(2003)BRAF mutation in metastasic melanoma: a possible association with clinical outcome Clin Cancer Res 9 3362-3368
[6]  
Marais R(2013)Low incidence of BRAFV600E mutation among melanoma patients in Ireland Cancer Res 73 23-235
[7]  
Lohmann JU(2012)BRAF mutations are frequent in malignant melanoma in Israeli population and predicts poor response to biochemotherapy Ann Oncol 23 373-6488
[8]  
Weigel D(2011)Clinicl correlates of NRAS and BRAF mutations in primary human melanoma Clin Cancer Res 17 229-328
[9]  
Wellbrock C(2003)NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression Clin Cancer Res 9 6483-599
[10]  
Karasarides MMR(2011)Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success? Br J Cancer 105 327-695
1234567